Education
About Us
Working with TipRanks
Follow Us
GT Biopharma (GTBP)
NASDAQ:GTBP
Total Valuation
GT Biopharma has a market cap or net worth of $13.08M. The enterprise value is -$2.30M.
Market Cap$13.08M
Enterprise Value-$2.30M
Share Statistics
GT Biopharma has 31,553,892 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,553,892
Owned by Insiders3.21%
Owned by Institutions0.52%
Financial Efficiency
GT Biopharma’s return on equity (ROE) is -4.90 and return on invested capital (ROIC) is -214.65%.
Return on Equity (ROE)-4.90
Return on Assets (ROA)-3.50
Return on Invested Capital (ROIC)-214.65%
Return on Capital Employed (ROCE)-2.15
Revenue Per Employee0.00
Profits Per Employee-28.35M
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of GT Biopharma is ―. GT Biopharma’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio0.75
Price to Fair Value0.75
Price to FCF-0.34
Price to Operating Cash Flow-0.18
PEG Ratio0.02
Income Statement
In the last 12 months, GT Biopharma had revenue of 0.00 and earned -28.35M in profits. Earnings per share was -6.25.
Revenue0.00
Gross Profit0.00
Operating Income-12.42M
Pretax Income-28.35M
Net Income-28.35M
EBITDA-34.32M
Earnings Per Share (EPS)-6.25
Cash Flow
In the last 12 months, operating cash flow was -12.91M and capital expenditures 0.00, giving a free cash flow of -12.91M billion.
Operating Cash Flow-12.91M
Free Cash Flow-12.91M
Free Cash Flow per Share-0.41
Dividends & Yields
GT Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.49
52-Week Price Change-82.75%
50-Day Moving Average0.58
200-Day Moving Average1.19
Relative Strength Index (RSI)35.42
Average Volume (3m)1.63M
Important Dates
GT Biopharma upcoming earnings date is Apr 1, 2026, TBA (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
GT Biopharma as a current ratio of 3.50, with Debt / Equity ratio of 0.00%
Current Ratio3.50
Quick Ratio3.50
Debt to Market Cap0.00
Net Debt to EBITDA0.20
Interest Coverage Ratio-97.81
Taxes
In the past 12 months, GT Biopharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
GT Biopharma EV to EBITDA ratio is 0.07, with an EV/FCF ratio of 0.19.
EV to Sales0.00
EV to EBITDA0.07
EV to Free Cash Flow0.19
EV to Operating Cash Flow0.19
Balance Sheet
GT Biopharma has $6.81M in cash and marketable securities with $0.00 in debt, giving a net cash position of $6.81M billion.
Cash & Marketable Securities$6.81M
Total Debt$0.00
Net Cash$6.81M
Net Cash Per Share$0.22
Tangible Book Value Per Share$1.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for GT Biopharma is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.00
Price Target Upside310.96% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast54.62%